Incorporation of human β-defensin-1 into immunoliposomes to facilitate targeted autophagy therapy of colon carcinoma  

作　　者：Ying Huang Xi-Ye Wang Jia-Yue Huang Zheng-Wei Huang 

机构地区：[1]College of Pharmacy,Jinan University,Guangzhou 511443,Guangdong Province,China

出　　处：《World Journal of Clinical Oncology》2025年第3期8-12,共5页世界临床肿瘤学杂志(英文)

基　　金：Supported by National Natural Science Foundation of China,No.82104070;Guangdong Universities Keynote Regions Special Funded Project,No.2022ZDZX2002。

摘　　要：Based on the discovery that humanβ-defensin-1(hBD-1)triggers autophagy in colon cancer cells and inhibits proliferation,we proposed the consideration of its druggability.As a protein,its stability,targetability and bioavailability must be improved.Compared with the traditional medicinal chemistry technology,nano-technology is more economical for increasing the druggability of hBD-1 and can be readily scaled up.Here,we propose an immunoliposome system containing hBD-1 to improve its stability and bioavailability.To enhance its targetability,anti-epidermal growth factor receptor(EGFR)antibodies were conjugated to the liposomal bilayer to produce immunoliposomes that can target EGFR,which is highly expressed in colon cancer cells.Although more studies are needed to su-pport clinical trials and large-scale manufacturing,these immunoliposomes have great potential as therapeutics.Thus,immunoliposomes are suitable nanovesicles to improve the druggability of hBD-1;however,additional basic and translational research of these systems is warranted.

关 键 词：Humanβ-defensin-1 IMMUNOLIPOSOMES Colon cancer SW620 AUTOPHAGY 

分 类 号：R73[医药卫生—肿瘤]